Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia
Journal of Internal Medicine2018Vol. 285(2), pp. 223–231
Citations Over TimeTop 10% of 2018 papers
Abstract
Systemic bevacizumab was highly effective to treat chronic bleeding in HHT. Further study is needed to confirm the magnitude of benefit and further define optimal dosing, treatment duration and long-term safety.
Related Papers
- → Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes(2011)5 cited
- → Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment(2010)3 cited
- → Two Cases of Leg Ulcer Caused by Bevacizumab(2017)1 cited
- → Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer(2014)
- Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases(2011)